Are We Ready for Cell Therapy to Treat Stroke?

• Published in: Frontiers in cell and developmental biology 2021-06, Vol.9, p.621645-621645
• Main Authors: Rascón-Ramírez, Fernando José, Esteban-García, Noelia, Barcia, Juan Antonio, Trondin, Albert, Nombela, Cristina, Sánchez-Sánchez-Rojas, Leyre
• Format: Article
• Language: English
• Subjects: administration route; Cell and Developmental Biology; cell therapeutic potential; clinical trial; diagnosis; stroke; therapy
• ISSN: 2296-634X; 2296-634X
• DOI: 10.3389/fcell.2021.621645

Clinical trials of cell therapies that target stroke started at the beginning of this century and they have experienced a significant boost in recent years as a result of promising data from basic research studies. The increase in the information available has paved the way to carry out more innovative and varied human studies. Efforts have focused on the search for a safe and effective treatment to stimulate neuro-regeneration in the brain and to reduce the sequelae of stroke in patients. Therefore, this review aims to evaluate the clinical trials using cell therapy to treat stroke published to date and assess their limitations. From 2000 to date, most of the published clinical trials have focused on phases I or II, and the vast majority of them demonstrate that stem cells are essentially safe to use when administered by different routes, with transient and mild adverse events that do not generally have severe consequences for health. In general, there is considerable variation in the trials in terms of statistical design, sample size, the cells used, the routes of administration, and the functional assessments (both at baseline and follow-up), making it difficult to compare the studies. From this general description, possibly the experimental protocol is the main element to improve in future studies. Establishing an adequate experimental and statistical design will be essential to obtain favorable and reliable results when conducting phase III clinical trials. Thus, it is necessary to standardize the criteria used in these clinical trials in order to aid comparison. Shortly, cell therapy will be a key approach in the treatment of stroke if adequate and comprehensive levels of recovery are to be achieved.